JP2020509780A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020509780A5 JP2020509780A5 JP2019552206A JP2019552206A JP2020509780A5 JP 2020509780 A5 JP2020509780 A5 JP 2020509780A5 JP 2019552206 A JP2019552206 A JP 2019552206A JP 2019552206 A JP2019552206 A JP 2019552206A JP 2020509780 A5 JP2020509780 A5 JP 2020509780A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- stem cell
- genetically engineered
- hla
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000000130 stem cell Anatomy 0.000 claims 30
- 238000000034 method Methods 0.000 claims 19
- 108090000623 proteins and genes Proteins 0.000 claims 18
- 210000004180 plasmocyte Anatomy 0.000 claims 10
- 210000003719 b-lymphocyte Anatomy 0.000 claims 9
- 210000000822 natural killer cell Anatomy 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 7
- 210000004027 cell Anatomy 0.000 claims 6
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims 5
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims 5
- 230000005859 cell recognition Effects 0.000 claims 5
- 230000000295 complement effect Effects 0.000 claims 5
- 239000003446 ligand Substances 0.000 claims 5
- 102100030346 Antigen peptide transporter 1 Human genes 0.000 claims 4
- 208000023275 Autoimmune disease Diseases 0.000 claims 4
- 102100025680 Complement decay-accelerating factor Human genes 0.000 claims 4
- 102100028970 HLA class I histocompatibility antigen, alpha chain E Human genes 0.000 claims 4
- 102100028967 HLA class I histocompatibility antigen, alpha chain G Human genes 0.000 claims 4
- 102100030595 HLA class II histocompatibility antigen gamma chain Human genes 0.000 claims 4
- 108010024164 HLA-G Antigens Proteins 0.000 claims 4
- 101000856022 Homo sapiens Complement decay-accelerating factor Proteins 0.000 claims 4
- 101000986085 Homo sapiens HLA class I histocompatibility antigen, alpha chain E Proteins 0.000 claims 4
- 101001082627 Homo sapiens HLA class II histocompatibility antigen gamma chain Proteins 0.000 claims 4
- 101000961414 Homo sapiens Membrane cofactor protein Proteins 0.000 claims 4
- 108010023335 Member 2 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 claims 4
- 102100039373 Membrane cofactor protein Human genes 0.000 claims 4
- 206010057249 Phagocytosis Diseases 0.000 claims 4
- 230000000890 antigenic effect Effects 0.000 claims 4
- 230000000415 inactivating effect Effects 0.000 claims 4
- 230000035772 mutation Effects 0.000 claims 4
- 244000052769 pathogen Species 0.000 claims 4
- 230000001717 pathogenic effect Effects 0.000 claims 4
- 230000008782 phagocytosis Effects 0.000 claims 4
- 102000004190 Enzymes Human genes 0.000 claims 3
- 108090000790 Enzymes Proteins 0.000 claims 3
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims 3
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 230000005847 immunogenicity Effects 0.000 claims 3
- 239000013638 trimer Substances 0.000 claims 3
- 101100382122 Homo sapiens CIITA gene Proteins 0.000 claims 2
- 101000991061 Homo sapiens MHC class I polypeptide-related sequence B Proteins 0.000 claims 2
- 108090000978 Interleukin-4 Proteins 0.000 claims 2
- 102100030300 MHC class I polypeptide-related sequence B Human genes 0.000 claims 2
- 102100026371 MHC class II transactivator Human genes 0.000 claims 2
- 108700002010 MHC class II transactivator Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 210000001671 embryonic stem cell Anatomy 0.000 claims 2
- 230000017188 evasion or tolerance of host immune response Effects 0.000 claims 2
- 230000002068 genetic effect Effects 0.000 claims 2
- 210000002809 long lived plasma cell Anatomy 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000010445 mica Substances 0.000 claims 2
- 229910052618 mica group Inorganic materials 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 210000002741 palatine tonsil Anatomy 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 210000001519 tissue Anatomy 0.000 claims 2
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 claims 1
- 102100022976 B-cell lymphoma/leukemia 11A Human genes 0.000 claims 1
- 102100027314 Beta-2-microglobulin Human genes 0.000 claims 1
- 108010029697 CD40 Ligand Proteins 0.000 claims 1
- 102100032937 CD40 ligand Human genes 0.000 claims 1
- 102100022002 CD59 glycoprotein Human genes 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 102000016574 Complement C3-C5 Convertases Human genes 0.000 claims 1
- 108010067641 Complement C3-C5 Convertases Proteins 0.000 claims 1
- 108010078015 Complement C3b Proteins 0.000 claims 1
- 108010077762 Complement C4b Proteins 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 102000000311 Cytosine Deaminase Human genes 0.000 claims 1
- 108010080611 Cytosine Deaminase Proteins 0.000 claims 1
- 102100037799 DNA-binding protein Ikaros Human genes 0.000 claims 1
- 101100174544 Danio rerio foxo1a gene Proteins 0.000 claims 1
- 101150074432 EDE1 gene Proteins 0.000 claims 1
- 101000823089 Equus caballus Alpha-1-antiproteinase 1 Proteins 0.000 claims 1
- 241000588724 Escherichia coli Species 0.000 claims 1
- 101150106966 FOXO1 gene Proteins 0.000 claims 1
- 241000710831 Flavivirus Species 0.000 claims 1
- 102100020715 Fms-related tyrosine kinase 3 ligand protein Human genes 0.000 claims 1
- 101710162577 Fms-related tyrosine kinase 3 ligand protein Proteins 0.000 claims 1
- 102100035427 Forkhead box protein O1 Human genes 0.000 claims 1
- 101000903703 Homo sapiens B-cell lymphoma/leukemia 11A Proteins 0.000 claims 1
- 101000897400 Homo sapiens CD59 glycoprotein Proteins 0.000 claims 1
- 101000599038 Homo sapiens DNA-binding protein Ikaros Proteins 0.000 claims 1
- 101001011441 Homo sapiens Interferon regulatory factor 4 Proteins 0.000 claims 1
- 101001032345 Homo sapiens Interferon regulatory factor 8 Proteins 0.000 claims 1
- 101000945331 Homo sapiens Killer cell immunoglobulin-like receptor 2DL4 Proteins 0.000 claims 1
- 101000601724 Homo sapiens Paired box protein Pax-5 Proteins 0.000 claims 1
- 101000596772 Homo sapiens Transcription factor 7-like 1 Proteins 0.000 claims 1
- 101000909637 Homo sapiens Transcription factor COE1 Proteins 0.000 claims 1
- 101000666382 Homo sapiens Transcription factor E2-alpha Proteins 0.000 claims 1
- 101000651211 Homo sapiens Transcription factor PU.1 Proteins 0.000 claims 1
- 206010062016 Immunosuppression Diseases 0.000 claims 1
- 102100030126 Interferon regulatory factor 4 Human genes 0.000 claims 1
- 102100038069 Interferon regulatory factor 8 Human genes 0.000 claims 1
- 108010002586 Interleukin-7 Proteins 0.000 claims 1
- 101150069255 KLRC1 gene Proteins 0.000 claims 1
- 102100033633 Killer cell immunoglobulin-like receptor 2DL4 Human genes 0.000 claims 1
- 101710177504 Kit ligand Proteins 0.000 claims 1
- 108010017736 Leukocyte Immunoglobulin-like Receptor B1 Proteins 0.000 claims 1
- 102100025584 Leukocyte immunoglobulin-like receptor subfamily B member 1 Human genes 0.000 claims 1
- 101100404845 Macaca mulatta NKG2A gene Proteins 0.000 claims 1
- 101100181101 Mus musculus Klra3 gene Proteins 0.000 claims 1
- 102100022682 NKG2-A/NKG2-B type II integral membrane protein Human genes 0.000 claims 1
- 102000004459 Nitroreductase Human genes 0.000 claims 1
- 102100037504 Paired box protein Pax-5 Human genes 0.000 claims 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 239000004098 Tetracycline Substances 0.000 claims 1
- 102000006601 Thymidine Kinase Human genes 0.000 claims 1
- 108020004440 Thymidine kinase Proteins 0.000 claims 1
- 102100024207 Transcription factor COE1 Human genes 0.000 claims 1
- 102100038313 Transcription factor E2-alpha Human genes 0.000 claims 1
- 102100027654 Transcription factor PU.1 Human genes 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 230000000735 allogeneic effect Effects 0.000 claims 1
- 108010081355 beta 2-Microglobulin Proteins 0.000 claims 1
- 230000024245 cell differentiation Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 230000002950 deficient Effects 0.000 claims 1
- 229960003722 doxycycline Drugs 0.000 claims 1
- 210000002889 endothelial cell Anatomy 0.000 claims 1
- 210000002950 fibroblast Anatomy 0.000 claims 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 claims 1
- 229960002963 ganciclovir Drugs 0.000 claims 1
- 230000004077 genetic alteration Effects 0.000 claims 1
- 231100000118 genetic alteration Toxicity 0.000 claims 1
- 230000004190 glucose uptake Effects 0.000 claims 1
- 230000003394 haemopoietic effect Effects 0.000 claims 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 1
- 230000004727 humoral immunity Effects 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 230000001506 immunosuppresive effect Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 230000002438 mitochondrial effect Effects 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000003472 neutralizing effect Effects 0.000 claims 1
- 108020001162 nitroreductase Proteins 0.000 claims 1
- 210000004248 oligodendroglia Anatomy 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
- 210000001778 pluripotent stem cell Anatomy 0.000 claims 1
- 230000029058 respiratory gaseous exchange Effects 0.000 claims 1
- 229960004641 rituximab Drugs 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 210000002536 stromal cell Anatomy 0.000 claims 1
- 229960002180 tetracycline Drugs 0.000 claims 1
- 229930101283 tetracycline Natural products 0.000 claims 1
- 235000019364 tetracycline Nutrition 0.000 claims 1
- 150000003522 tetracyclines Chemical class 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022160907A JP7731579B2 (ja) | 2017-03-20 | 2022-10-05 | 細胞並びにその使用方法及び製造方法 |
| JP2025134751A JP2025169335A (ja) | 2017-03-20 | 2025-08-13 | 細胞並びにその使用方法及び製造方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762473564P | 2017-03-20 | 2017-03-20 | |
| US62/473,564 | 2017-03-20 | ||
| PCT/US2018/023288 WO2018175390A1 (en) | 2017-03-20 | 2018-03-20 | Cells and methods of uses and making the same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022160907A Division JP7731579B2 (ja) | 2017-03-20 | 2022-10-05 | 細胞並びにその使用方法及び製造方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020509780A JP2020509780A (ja) | 2020-04-02 |
| JP2020509780A5 true JP2020509780A5 (enExample) | 2021-04-30 |
Family
ID=63585747
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019552206A Pending JP2020509780A (ja) | 2017-03-20 | 2018-03-20 | 細胞並びにその使用方法及び製造方法 |
| JP2022160907A Active JP7731579B2 (ja) | 2017-03-20 | 2022-10-05 | 細胞並びにその使用方法及び製造方法 |
| JP2025134751A Pending JP2025169335A (ja) | 2017-03-20 | 2025-08-13 | 細胞並びにその使用方法及び製造方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022160907A Active JP7731579B2 (ja) | 2017-03-20 | 2022-10-05 | 細胞並びにその使用方法及び製造方法 |
| JP2025134751A Pending JP2025169335A (ja) | 2017-03-20 | 2025-08-13 | 細胞並びにその使用方法及び製造方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20200095543A1 (enExample) |
| EP (1) | EP3601528A4 (enExample) |
| JP (3) | JP2020509780A (enExample) |
| CN (2) | CN119120363A (enExample) |
| AU (2) | AU2018239320B2 (enExample) |
| CA (1) | CA3094322A1 (enExample) |
| WO (1) | WO2018175390A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110494565A (zh) | 2016-12-02 | 2019-11-22 | 朱诺治疗学股份有限公司 | 工程化b细胞及相关组合物和方法 |
| CN109234232A (zh) * | 2018-09-30 | 2019-01-18 | 杭州华安单抗生物技术有限公司 | 兔外周血b细胞的培养体系及培养方法、抗体的制备方法和应用 |
| US11162079B2 (en) | 2019-05-10 | 2021-11-02 | The Regents Of The University Of California | Blood type O Rh-hypo-immunogenic pluripotent cells |
| JP2022543112A (ja) | 2019-08-01 | 2022-10-07 | サナ バイオテクノロジー，インコーポレイテッド | Ｄｕｘ４発現細胞およびそれらの使用 |
| EP4017508A1 (en) | 2019-08-23 | 2022-06-29 | Sana Biotechnology, Inc. | Cd24 expressing cells and uses thereof |
| CN115135330A (zh) * | 2019-10-10 | 2022-09-30 | 纽约干细胞基金会有限公司 | 修饰的干细胞及其使用方法 |
| JP2023502269A (ja) * | 2019-11-20 | 2023-01-23 | ヴィータ セラピューティクス インク． | 低免疫原性の筋肉前駆体細胞の遺伝子改変的調製方法 |
| MX2022011831A (es) * | 2020-03-25 | 2023-01-04 | Sana Biotechnology Inc | Células neurales hipoinmunogénicas para el tratamiento de trastornos y afecciones neurológicas. |
| CN111548998B (zh) * | 2020-04-23 | 2022-08-05 | 中山大学 | 一种分泌pd-1抗体的长寿浆细胞及其制备方法与应用 |
| BR112022021617A2 (pt) * | 2020-04-27 | 2023-01-03 | Sana Biotechnology Inc | Dosagem repetida de células hipoimunogênicas |
| CN111849909A (zh) * | 2020-06-03 | 2020-10-30 | 暨南大学 | 一种用于快速高效扩增人b淋巴细胞体外扩增的细胞及其构建方法 |
| WO2021251271A1 (ja) * | 2020-06-09 | 2021-12-16 | 帝人株式会社 | Ｍｈｃ－クラスｉ発現が抑制された細胞 |
| CN114015656A (zh) * | 2020-07-15 | 2022-02-08 | 南京北恒生物科技有限公司 | 用于同种异体移植的工程化免疫细胞 |
| JP7623020B2 (ja) * | 2020-07-15 | 2025-01-28 | バイオヘン セラピューティクス リミテッド | 同種異系移植のための操作された免疫細胞 |
| CN114457024A (zh) * | 2020-10-30 | 2022-05-10 | 未来智人再生医学研究院(广州)有限公司 | 一种表达IL-4Rα阻断物的多能干细胞或其衍生物及应用 |
| US11591381B2 (en) | 2020-11-30 | 2023-02-28 | Crispr Therapeutics Ag | Gene-edited natural killer cells |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| AU2021392032A1 (en) | 2020-12-03 | 2023-06-22 | Century Therapeutics, Inc. | Genetically engineered cells and uses thereof |
| EP4263600A1 (en) | 2020-12-18 | 2023-10-25 | Century Therapeutics, Inc. | Chimeric antigen receptor systems with adaptable receptor specificity |
| EP4271798A1 (en) | 2020-12-30 | 2023-11-08 | CRISPR Therapeutics AG | Compositions and methods for differentiating stem cells into nk cells |
| KR20230137900A (ko) | 2020-12-31 | 2023-10-05 | 사나 바이오테크놀로지, 인크. | Car-t 활성을 조정하기 위한 방법 및 조성물 |
| JP2024518632A (ja) * | 2021-05-20 | 2024-05-01 | 中国科学院広州生物医薬与健康研究院 | 体液免疫系の再生方法およびその使用 |
| CN114181968B (zh) * | 2022-02-11 | 2022-07-19 | 北京干细胞与再生医学研究院 | 一种具备b谱系分化潜能的人造血祖细胞的制备方法及其应用 |
| EP4479084A1 (en) | 2022-02-14 | 2024-12-25 | Sana Biotechnology, Inc. | Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells |
| MA71320A (fr) | 2022-07-01 | 2025-04-30 | Novo Nordisk A/S | Amélioration de la différenciation neuronale de cellules progénitrices neurales du mésencéphale ventral |
| CN116008564B (zh) * | 2023-01-09 | 2025-07-22 | 中南大学湘雅二医院 | 检测2-nbdg阳性b细胞的试剂在制备诊断和/或预后自身免疫糖尿病制剂中的应用 |
| CN118497129A (zh) * | 2023-02-16 | 2024-08-16 | 士泽生物医药（苏州）有限公司 | 通用型细胞及其制备方法 |
| WO2024238387A1 (en) * | 2023-05-12 | 2024-11-21 | Nkmax Co., Ltd. | Method of treating alzheimer's disease with expanded natural killer cells |
| WO2025003393A1 (en) | 2023-06-30 | 2025-01-02 | Novo Nordisk A/S | Enhancing neuronal differentiation of neural progenitor cells |
| WO2025096757A1 (en) | 2023-11-01 | 2025-05-08 | Sana Biotechnology, Inc. | Hypoimmunogenic cd22-targeted car t cells for the treatment of relapsed and/or refractory b cell lymphomas |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5573940A (en) * | 1989-06-12 | 1996-11-12 | Oklahoma Medical Research Foundation | Cells expressing high levels of CD59 |
| EP1463803B1 (en) * | 2001-12-07 | 2018-02-14 | Asterias Biotherapeutics, Inc. | Hematopoietic cells from human embryonic stem cells |
| GB2398783A (en) * | 2003-02-26 | 2004-09-01 | Antonio Lanzavecchia | A method for producing immortalised human B memory lymphocytes |
| JP4667451B2 (ja) * | 2004-04-05 | 2011-04-13 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Ｎｋｇ２ｄの調節 |
| RU2559524C2 (ru) * | 2008-06-27 | 2015-08-10 | Мерюс Б.В. | Продуцирующие антитела млекопитающие, не являющиеся человеком |
| US9428732B2 (en) * | 2011-12-05 | 2016-08-30 | Primorigen Biosciences, Inc. | Compositions and methods for differentiating pluripotent stem cells into primitive blood cells and uses thereof |
| EP2838548B1 (en) * | 2012-04-17 | 2023-07-19 | University of Washington through its Center for Commercialization | Hla class ii deficient cells, hla class i deficient cells capable of expressing hla class ii proteins, and uses thereof |
| CN104046593A (zh) * | 2013-03-14 | 2014-09-17 | 浙江大学 | 一种低免疫原性的人细胞及其制备方法 |
| EP3096609B1 (en) * | 2014-01-24 | 2021-09-22 | Children's Medical Center Corporation | High-throughput mouse model for optimizing antibody affinities |
| AU2015360502A1 (en) * | 2014-12-10 | 2017-06-29 | Regents Of The University Of Minnesota | Genetically modified cells, tissues, and organs for treating disease |
| HK1254190A1 (zh) * | 2015-05-08 | 2019-07-12 | President And Fellows Of Harvard College | 通用供体干细胞和相关方法 |
| KR20250141836A (ko) * | 2015-11-04 | 2025-09-29 | 페이트 세러퓨틱스, 인코포레이티드 | 만능 세포의 유전자 조작 |
| MX2019008413A (es) * | 2017-01-13 | 2019-09-13 | Univ California | Celulas pluripotentes inmunodiseñadas. |
| WO2018140890A1 (en) * | 2017-01-29 | 2018-08-02 | Zequn Tang | Methods of immune modulation against foreign and/or auto antigens |
-
2018
- 2018-03-20 EP EP18771866.3A patent/EP3601528A4/en active Pending
- 2018-03-20 CN CN202411279640.0A patent/CN119120363A/zh active Pending
- 2018-03-20 CA CA3094322A patent/CA3094322A1/en active Pending
- 2018-03-20 WO PCT/US2018/023288 patent/WO2018175390A1/en not_active Ceased
- 2018-03-20 CN CN201880032723.6A patent/CN110637083A/zh active Pending
- 2018-03-20 JP JP2019552206A patent/JP2020509780A/ja active Pending
- 2018-03-20 AU AU2018239320A patent/AU2018239320B2/en active Active
- 2018-03-30 US US16/495,318 patent/US20200095543A1/en not_active Abandoned
-
2022
- 2022-10-05 JP JP2022160907A patent/JP7731579B2/ja active Active
-
2023
- 2023-02-03 US US18/164,502 patent/US20230313131A1/en active Pending
-
2025
- 2025-01-23 AU AU2025200450A patent/AU2025200450A1/en active Pending
- 2025-08-13 JP JP2025134751A patent/JP2025169335A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020509780A5 (enExample) | ||
| JP2022188202A (ja) | 細胞並びにその使用方法及び製造方法 | |
| JP7649258B2 (ja) | 癌を治療するための組成物および方法 | |
| US9907820B2 (en) | Polyclonal gamma delta T cells for immunotherapy | |
| JP6866988B2 (ja) | 誘導された樹状細胞およびその使用 | |
| JP2020108398A (ja) | Ｃａｒ発現ベクター及びｃａｒ発現ｔ細胞 | |
| US20110052554A1 (en) | Methods for off-the- shelf tumor immunotherapy using allogeneic t-cell precursors | |
| US20050238626A1 (en) | Antigen specific T cell therapy | |
| CA3028829A1 (en) | Genetically modified t lymphocytes | |
| WO2019154313A1 (zh) | 一种分离的嵌合抗原受体以及包含其的修饰t细胞及用途 | |
| CN116348496A (zh) | Bcma嵌合抗原受体 | |
| Brehm et al. | Humanized mice in translational immunology | |
| JP2023532917A (ja) | Ｂ細胞のｂ２ｍ遺伝子座を編集するための方法および組成物 | |
| CN117106061B (zh) | 靶向巨细胞病毒抗原的tcr和表达其的t细胞及应用 | |
| US20190307800A1 (en) | Methods for off-the-shelf-tumor immunotherapy using allogeneic t-cell precursors | |
| CN111499766A (zh) | 针对慢性淋巴细胞白血病的免疫效应细胞、其制备方法和应用 | |
| CN117736300A (zh) | 靶向巨细胞病毒pp65的T细胞受体和表达其的T细胞及应用 | |
| Arjomandnejad et al. | CAR-T regulatory (CAR-Treg) cells: engineering and applications. Biomedicines 2022; 10: 287 | |
| US20250025499A1 (en) | T cell immunotherapy for hematologic malignancies having an sf3b1 mutation | |
| EP2953644B1 (en) | Induced dendritic cells and uses thereof | |
| WO2025232819A1 (en) | Immunotherapies using engineered cells for enhanced bone marrow homing | |
| WO2025231213A2 (en) | Modified b cells and methods for use thereof | |
| US20230272431A1 (en) | Methods and compositions for editing the b2m locus in b cells | |
| Wang | Generation of hypoimmunogenic T cells from genetically engineered allogeneic iPS cells for off-the-shelf cancer immunotherapy | |
| JPWO2022006309A5 (enExample) |